Mizuho raises Verastem stock price target on strong trial data
Mizuho raised its price target on Verastem Inc. (VSTM) to $14 from $13, citing strong clinical trial data for its oral KRAS G12D inhibitor. The stock trades at $7.71, with analysts' targets ranging from $12 to $24. Verastem plans a Phase 3 study and completed a $250 million financing. Multiple analysts maintain positive ratings, with price targets up to $19.
How this was made
The 30-second read
Why it matters
The data strengthens the company's pipeline, prompting analysts to raise targets and could attract additional capital.
Market read
First report of positive trial data for VSTM, leading to analyst upgrades and potential short‑term price upside.
What to watch
Potential dilution from the $250 M financing and the need for further regulatory approval.
Background
Verastem reported its first U.S. clinical results for VS-7375, showing efficacy in pancreatic ductal adenocarcinoma and plans a pivotal Phase 3 study.
Ticker impact
Mizuho raised its price target on Verastem (VSTM) to $14 after the company released positive Phase 1/2 trial data for its KRAS G12D inhibitor VS-7375.
likely upward pressure as investors price in the favorable trial results and higher target.
The trial data is a primary disclosure for a biotech and Mizuho's target raise signals a material re‑rating, which typically drives short‑term buying.
Market effects
Positive KRAS G12D data may lift sentiment across the oncology biotech sector.
US biotech investors likely to react, with limited broader market effect.
Limited to biotech investors; no major macro impact.
Counterpoint
If the Phase 3 data later fails to confirm early signals, the price could reverse sharply.
Key entities
- companyVerastem Inc.
Biotech firm developing KRAS G12D inhibitors.
- analystMizuho
Investment bank that raised its price target on VSTM.
